Skip to main content
. Author manuscript; available in PMC: 2024 Jul 21.
Published in final edited form as: Lancet. 2022 Sep 5;400(10356):921–972. doi: 10.1016/S0140-6736(22)01273-9

Figure 4: Availability of pharmacological therapies (A) and non-pharmacological therapies (B) for chronic obstructive pulmonary disease in lower-middle-income, upper-middle-income, and high-income countries.

Figure 4:

LAMA=long-acting muscarinic antagonist. LABA=long-acting β agonist. SAMA=short-acting muscarinic antagonist. SABA=short-acting β agonist.